--- title: "Bicycle Therapeutics (NASDAQ:BCYC) Sets New 12-Month Low - Should You Sell?" description: "Bicycle Therapeutics (NASDAQ:BCYC) shares hit a new 52-week low of $8.25, closing at $8.64. Analysts have mixed ratings, with price targets ranging from $15 to $33. The company reported a quarterly EP" type: "news" locale: "en" url: "https://longbridge.com/en/news/234084733.md" published_at: "2025-04-01T15:11:46.000Z" --- # Bicycle Therapeutics (NASDAQ:BCYC) Sets New 12-Month Low - Should You Sell? > Bicycle Therapeutics (NASDAQ:BCYC) shares hit a new 52-week low of $8.25, closing at $8.64. Analysts have mixed ratings, with price targets ranging from $15 to $33. The company reported a quarterly EPS of ($0.75), exceeding estimates, but revenue fell short at $3.70 million. Insider selling has occurred, with significant shares sold by executives. Hedge funds have also adjusted their positions, with Barclays increasing its stake by 878.3%. The stock has a market cap of $582.89 million and a negative net margin of 450.64%. Bicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report)'s share price reached a new 52-week low during mid-day trading on Monday . The company traded as low as $8.25 and last traded at $8.64, with a volume of 418 shares trading hands. The stock had previously closed at $8.97. Get **Bicycle Therapeutics** alerts: ## Wall Street Analysts Forecast Growth Several research firms have recently commented on BCYC. Stephens reaffirmed an "equal weight" rating and set a $15.00 price target on shares of Bicycle Therapeutics in a research report on Wednesday, January 22nd. HC Wainwright reiterated a "buy" rating and issued a $33.00 price target on shares of Bicycle Therapeutics in a research report on Wednesday, February 26th. JMP Securities cut their price objective on shares of Bicycle Therapeutics from $32.00 to $26.00 and set a "market outperform" rating for the company in a research report on Wednesday, December 18th. Needham & Company LLC restated a "buy" rating and issued a $30.00 price objective on shares of Bicycle Therapeutics in a research note on Tuesday, March 11th. Finally, B. Riley reduced their price target on Bicycle Therapeutics from $28.00 to $17.00 and set a "neutral" rating for the company in a research report on Friday, December 13th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, Bicycle Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $29.14. **Get Our Latest Research Report on BCYC** ## Bicycle Therapeutics Trading Down 6.1 % The business has a 50-day moving average price of $11.32 and a 200 day moving average price of $17.52. The stock has a market capitalization of $582.89 million, a P/E ratio of -2.57 and a beta of 1.12. Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($0.75) EPS for the quarter, topping analysts' consensus estimates of ($0.85) by $0.10. The business had revenue of $3.70 million during the quarter, compared to analysts' expectations of $5.47 million. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The business's revenue was down 30.2% on a year-over-year basis. During the same period last year, the company posted ($1.16) EPS. On average, sell-side analysts predict that Bicycle Therapeutics plc will post -3.06 earnings per share for the current fiscal year. ## Insider Transactions at Bicycle Therapeutics In related news, CAO Travis Alvin Thompson sold 2,686 shares of the business's stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $15.00, for a total value of $40,290.00. Following the completion of the transaction, the chief accounting officer now owns 32,146 shares of the company's stock, valued at $482,190. The trade was a 7.71 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Kevin Lee sold 9,038 shares of the stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $14.09, for a total value of $127,345.42. Following the sale, the chief executive officer now directly owns 495,026 shares in the company, valued at $6,974,916.34. This trade represents a 1.79 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 27,677 shares of company stock worth $392,413. 8.50% of the stock is currently owned by insiders. ## Institutional Investors Weigh In On Bicycle Therapeutics Hedge funds have recently made changes to their positions in the stock. Barclays PLC grew its position in shares of Bicycle Therapeutics by 878.3% in the 4th quarter. Barclays PLC now owns 2,612 shares of the company's stock worth $37,000 after buying an additional 2,345 shares during the last quarter. Avior Wealth Management LLC acquired a new stake in Bicycle Therapeutics in the fourth quarter valued at approximately $57,000. JPMorgan Chase & Co. grew its holdings in Bicycle Therapeutics by 26.8% in the third quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company's stock worth $191,000 after purchasing an additional 1,782 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of Bicycle Therapeutics by 30.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,329 shares of the company's stock worth $131,000 after purchasing an additional 2,191 shares in the last quarter. Finally, Erste Asset Management GmbH purchased a new stake in shares of Bicycle Therapeutics during the 3rd quarter valued at $325,000. 86.15% of the stock is currently owned by hedge funds and other institutional investors. ## About Bicycle Therapeutics (Get Free Report) Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. ## See Also - Five stocks we like better than Bicycle Therapeutics - What is the FTSE 100 index? - AT&T and Verizon: 2 Telecom Titans for a Tariff-Proof Play - Using the MarketBeat Dividend Tax Calculator - 3 High-Performing Tech ETFs to Diversify Your Portfolio - Why Invest in High-Yield Dividend Stocks? - Netflix Poised for Significant Rally as a Safe Haven Stock *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.* ## Should You Invest $1,000 in Bicycle Therapeutics Right Now? Before you consider Bicycle Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicycle Therapeutics wasn't on the list. While Bicycle Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [BCYC.US - Bicycle Therapeutics](https://longbridge.com/en/quote/BCYC.US.md) - [BCS.US - Barclays](https://longbridge.com/en/quote/BCS.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Bicycle Therapeutics (BCYC) 预计将在周二发布季度财报 | Bicycle Therapeutics（纳斯达克代码：BCYC）定于 2 月 24 日发布 2025 年第四季度财报，分析师预计每股亏损 1.00 美元。该公司股票开盘价为 5.24 美元，市值为 3.635 亿美元。最近的内部交易包括首 | [Link](https://longbridge.com/en/news/276110215.md) | | Bicycle Therapeutics plc 为首席财务官 Travis Thompson 制定了新的薪酬方案 | Bicycle Therapeutics plc 宣布其新任首席财务官 Travis Thompson 的年基本工资为 500,000 美元，并将从 2026 年 1 月 29 日起获得相当于其基本工资 50% 的年度目标奖金。此外，Tho | [Link](https://longbridge.com/en/news/274652142.md) | | 拉斯克鲁塞斯警方将召开新闻发布会，讨论涉及警员的枪击事件 | 拉斯克鲁塞斯警方将于 2 月 17 日举行新闻发布会，向公众更新 2 月 8 日发生的涉及警员的枪击事件。事件中，一名警员试图拘留 28 岁的约翰尼·雷·莫拉莱斯，因其涉嫌盗窃自行车，期间莫拉莱斯向警员开枪，警员进行了还击。莫拉莱斯在现场被 | [Link](https://longbridge.com/en/news/276077648.md) | | 加州新法案将要求电动自行车安装车牌 | 加利福尼亚州的一项新法案，众议院法案 1942，提议将 2 类和 3 类电动自行车注册到机动车辆管理局（DMV），并显示车牌。此项变更旨在使电动自行车的管理更类似于机动车，要求提供所有权证明，并对未注册使用处以罚款。该法案还设立了电动自行车 | [Link](https://longbridge.com/en/news/276322851.md) | | Bicycle Therapeutics 宣布领导层变动，并任命新的董事会成员 | Bicycle Therapeutics plc 宣布了几项管理层变动。Travis Thompson 被任命为新的首席财务官，接替 Alethia Young。Michael Method 将接任首席医学官，替换 Eric Westin。 | [Link](https://longbridge.com/en/news/274651009.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.